Table of Contents
ISRN Neurology
Volume 2011 (2011), Article ID 464572, 4 pages
http://dx.doi.org/10.5402/2011/464572
Research Article

Penicillamine Neurotoxicity: An Hypothesis

Department of Medicine, Medical School, University of Cambridge, Cambridge CB2 2QQ, UK

Received 16 March 2011; Accepted 17 May 2011

Academic Editors: C.-M. Chen and A. Quattrini

Copyright © 2011 J. M. Walshe. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. H. Scheinberg and I. Sternlieb, Major Problems in Internal Medicine XXIII Wilson's, W.B. Saunders, Disease, Pa, USA, 1984.
  2. J. M. Walshe, “Penicillamine: the treatment of first choice for patients with Wilson's disease,” Movement Disorders, vol. 14, no. 4, pp. 545–550, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. J. N. Cumings, “The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration,” Brain, vol. 71, no. 4, pp. 410–415, 1948. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Denny-Brown and H. Porter, “The effect of BAL (2,3 dimercapropropanol on hhepato-lenticular degeneration (Wilson's disease),” The New England Journal of Medicine, vol. 145, pp. 917–925, 1951. View at Google Scholar
  5. J. N. Cumings, “The effects of B.A.L. in hepatolenticular degeneration,” Brain, vol. 74, no. 1, pp. 10–22, 1951. View at Publisher · View at Google Scholar · View at Scopus
  6. L. L. Uzman, “On the relationship of urinary copper excretion to the aminoaciduria in Wilson's disease (hepatolenticular degeneration),” The American Journal of the Medical Sciences, vol. 226, no. 6, pp. 645–652, 1953. View at Google Scholar · View at Scopus
  7. L. L. Uzman and B. Hood, “The familial nature of the amino-aciduria of Wilson's disease (hepatolenticular degeneration),” The American Journal of the Medical Sciences, vol. 223, no. 4, pp. 392–400, 1952. View at Google Scholar · View at Scopus
  8. L. L. Uzman, F. L. Iber, T. C. Chalmeres, and M. Knowlton, “The mechanism of copper deposition in the liver in hepatolenticular degeneration (Wilson's disease),” The American Journal of the Medical Sciences, vol. 231, no. 5, pp. 511–518, 1956. View at Google Scholar · View at Scopus
  9. D. Denny-Brown, “Hepatolenticular degeneration (Wilson's disease) two different components,” The New England Journal of Medicine, vol. 270, pp. 1149–1156, 1964. View at Google Scholar · View at Scopus
  10. A. M. Asatoor, M. D. Milne, and J. M. Walshe, “Urinary excretion of peptides and of hydroxyproline in Wilson's disease,” Clinical Science and Molecular Medicine, vol. 51, no. 4, pp. 369–378, 1976. View at Google Scholar · View at Scopus
  11. J. M. Walshe, “Penicillamine, a new oral therapy for Wilson's disease,” The American Journal of Medicine, vol. 21, no. 4, pp. 487–495, 1956. View at Google Scholar · View at Scopus
  12. J. E. Wilson and V. Du Vigneaud, “Inhibition of the growth of the rat by L-penicillamine and its prevention by aminoethanol and related compounds,” The Journal of Biological Chemistry, vol. 184, no. 1, pp. 63–70, 1950. View at Google Scholar · View at Scopus
  13. J. C. Crawhall, E. F. Scowen, and R. W. E. Watts, “Effect of penicillamine on cystinuria,” British Medical Journal, vol. 1, no. 5330, pp. 588–590, 1963. View at Google Scholar · View at Scopus
  14. B. S. Hartley and J. M. Walshe, “Penicillamine and mixed disulphide excretion in Wilson's disease,” The Lancet, vol. 282, no. 7305, pp. 434–435, 1963. View at Google Scholar · View at Scopus
  15. J. M. Walshe, “Management of penicillamine nephropathy in Wilson's disease: a new chelating agent,” The Lancet, vol. 2, no. 7635, pp. 1401–1402, 1969. View at Google Scholar · View at Scopus
  16. “Penicillamine,” Postgraduate Medical Journal, vol. 44, supplement, 1968.
  17. B. I. Hoffbrand, “Penicillamine: recent work,” Postgraduate Medical Journal, vol. 50, supplement 2, 1974. View at Google Scholar
  18. “Penicillamine at 21: it's place in therapeurics now,” Proceedings of the Royal Society of Medicine, vol. 70, supplement 3, 1977.
  19. “International symposium on penicillamine,” Journal of Rheumatology, vol. 8, supplement 7, 1981.
  20. J. M. Walshe, “Penicillamine and the SLE syndrome,” Journal of Rheumatology, vol. 8, supplement 7, pp. 155–160, 1981. View at Google Scholar · View at Scopus
  21. M. E. Nimni, “Mechanism of inhibition of collagen crosslinking by penicillamine,” Journal of Rheumatology, vol. 5, supplement 7, pp. 65–72, 1981. View at Google Scholar
  22. K. Gibbs and J. M. Walshe, “Interruption of the tryptophan-nicotinic acid pathway by penicillamine-induced pyridoxine deficiency in patients with Wilson's disease and in experimental animals,” Annals of the New York Academy of Sciences, vol. 166, no. 1, pp. 158–169, 1969. View at Google Scholar · View at Scopus
  23. J. M. Walshe and M. Yealland, “Chelation treatment of neurological Wilson's disease,” Quarterly Journal of Medicine, vol. 86, no. 3, pp. 197–204, 1993. View at Google Scholar · View at Scopus
  24. M. Miki, “Penicillamine as antioxidant,” Methods in Enzymology, vol. 234, pp. 542–547, 1994. View at Publisher · View at Google Scholar · View at Scopus
  25. A. G. Bearn, T. F. Yu, and A. B. Gutman, “Renal function in Wilson's disease,” The Journal of Clinical Investigation, vol. 36, no. 7, pp. 1107–1114, 1957. View at Google Scholar · View at Scopus
  26. A. So and B. Thorens, “Uric acid transport and disease,” Journal of Clinical Investigation, vol. 120, no. 6, pp. 1791–1799, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. A. Ascherio, P. H. Peteer, P. A. LeWitt et al., “Urate as a predictor of the rate of clinical decline in Parkinson's disease,” Archives of Neurology, vol. 66, no. 12, pp. 1460–1468, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. R. A. Peters, Biochemical Lesions and Lethal Synthesis, Pergamon Press, London, UK, 1963.
  29. K. Gibbs and J. M. Walshe, “Studies with 35S-labelled DL-penicillamine in patients with Wilson's disease,” The Quarterly Journal of Medicine, vol. 40, no. 158, pp. 275–287, 1971. View at Google Scholar · View at Scopus
  30. F. Challenger and J. M. Walshe, “Fetor hepaticus,” The Lancet, vol. 265, no. 6877, pp. 1239–1241, 1955. View at Google Scholar · View at Scopus
  31. J. W. Purdie, H. A. Gillis, and N. V. Klassen, “The pulse radiolysis of penicillamine and penicillamine disulfide in aqueous solution,” Canadian Journal of Chemistry, vol. 51, no. 18, pp. 3132–3142, 1973. View at Google Scholar · View at Scopus